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Cytomegalovirus (CMV) is the single most important infectious agent
affecting recipients of organ transplants. To evaluate the incidence
and the clinical importance of CMV infection in renal transplants in
Brazil, 37 patients submitted to renal allograft transplants were tested
periodically for the presence of cytomegalovirus DNA in urine using
the polymerase chain reaction (PCR), and for the presence of IgM and
IgG antibodies against CMV by enzyme-linked immunosorbent assay
(ELISA) and indirect immunofluorescence (IFI). The PCR-amplified
products were detected by gel electrophoresis and confirmed by dot-
blot hybridization with oligonucleotide probes. Thirty-two of the 37
patients (86.4%) were positive by at least one of the three methods. In
six patients, PCR was the only test which detected the probable CMV
infection. Ten patients had a positive result by PCR before transplan-
tation. In general, the diagnosis was achieved earlier by PCR than by
serologic tests. Active infection occurred more frequently during the
first four months after transplantation. Sixteen of the 32 patients
(50%) with active CMV infection presented clinical symptoms con-
sistent with CMV infection. Five patients without evidence of active
CMV infection by the three tests had only minor clinical manifesta-
tions during follow-up. Our results indicate that PCR is a highly
sensitive procedure for the early detection of CMV infection and that
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Cytomegalovirus (CMV) infection is an
important cause of morbidity and mortality
in immunosuppressed patients, particularly
among allograft recipients, whose number
has increased markedly in recent years. The
ubiquity of this virus, its propensity to be
reactivated when host defenses are compro-
mised and its ability to disseminate to several
organs are characteristics which help explain
its frequent occurrence in the transplanted
population. Numerous studies have shown
that the majority of patients develop evi-
dence of active CMV infection following
kidney transplantation. Although most of
these individuals have asymptomatic infec-
tions, others have clinical manifestations of
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illness (overt CMV disease) ranging from
high fever to death. The rapid and specific
diagnosis of active CMV infection in these
patients is important since its manifestations
may resemble those of transplant rejection
but require distinct management (1-6). Sev-
eral procedures for the detection of CMV are
available, including conventional virus cul-
ture, shell-vial, serology tests, antigenemia
and PCR (7-12). In this paper we report the
prevalence and clinical impact of CMV in-
fection identified by serological tests and by




Thirty-seven patients submitted to kid-
ney transplantation at the Kidney Transplant
Unit of the Department of Internal Medi-
cine, University Hospital, State University
of Campinas, SP, Brazil, were studied pro-
spectively over a two-year period. Informed
consent was obtained from all patients and
the protocol was approved by the Hospitals
Ethics Committee.
The immunosuppressive regimen used
during the study included corticosteroids,
azathioprine, and cyclosporine. Episodes of
rejection were documented by renal biopsy
and treated with increased doses of oral cor-
ticosteroids for mild episodes and 500 mg
intravenous pulses of methylprednisolone,
or the monoclonal antibody OKT3, or both,
for moderate or severe episodes.
Clinical and laboratory records were re-
viewed for evidence of symptoms attributed
to CMV disease.
Clinical specimens
Urine. Urine samples were obtained from
renal allograft donors and recipients imme-
diately prior to transplantation and from re-
cipients once a month for approximately one
year post-transplant.
Serum. Serum samples were collected at
the same time as urine specimens and were
tested by serological methods for CMV (en-
zyme-linked immunosorbent assay (ELISA)
and indirect immunofluorescence (IFI)). All
specimens for a given patient were analyzed
in the same batch.
Serology
Serum CMV IgG and IgM antibodies
were determined by ELISA (13) and IFI
(14).
PCR
CMV DNA determination in urine speci-
mens was carried out by PCR according to
the procedure of Demmler et al. (15) using
three pairs of primers for amplification. Each
pair was designed for the amplification of
different regions of the viral genome (16).
The reaction buffer contained 50 mM KCl,
10 mM Tris-HCl, pH 8.3, 1.5 mM MgCl2,
0.01% gelatin, 200 µM of each of the four
deoxynucleotide triphosphates (dATP, dCTP,
dTTP and dGTP), 2.4 µM of each primer,
water and sample (1.5 µl), for a total volume
of 100 µl. The reaction mixture was overlaid
with 100 µl of mineral oil and the tubes were
placed in a boiling water bath for 7 min.
After boiling, 0.5 µl (2.5 U) of Thermus
aquaticus (Taq) polymerase was added. The
amplification reaction was performed in a
DNA Thermal Cycler (Perkin-Elmer/Cetus,
Norwalk, CT, USA). The samples were
heated to 94oC for 90 s to denature DNA,
cooled to 55oC for 90 s for annealing and
then heated to 72oC for 120 s for extension.
In the final cycle, an extension period of 7
min was done. A total of 40 cycles were
performed and 5 µl of the amplified product
was detected by direct analysis on 2% aga-
rose minigels and by a dot-blot hybridization
assay using oligonucleotide probes. A 159-,
400- and 435-base pair band was seen when
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samples were amplified using IE, LA and
MIE primers, respectively.
After electrophoresis, the remaining PCR
product was tested by dot-blot. For dot-blot
analysis (15), 10 µl of the reaction mixture
was mixed with 190 µl of 2 M sodium chlo-
ride and then denatured by adding 10 µl of
10 M sodium hydroxide for 15 min. The
sample was then neutralized by adding 100
µl of 3 M sodium acetate, pH 5.5. The DNA
was immediately applied to a nylon mem-
brane by vacuum filtration, and the mem-
branes were dried by heating in a vacuum
oven at 80oC for 1 h and hybridized with a
homologous 32P-labeled synthetic oligonucle-
otide probe in a hybridization solution con-
taining 1% SDS and 6x SSPE buffer (0.9 M
NaCl, 60 mM NaH2PO4, pH 7.4, and 6 mM
Na2EDTA) for 18 h. Three 10-min washes
were subsequently performed in 6x SSPE
and 1% SDS at room temperature. A final
wash was performed in 1x SSPE and 1%
SDS for 3 min at 65oC. The bound probe was
detected by autoradiography at -70oC for
18 h.
Occurrence of CMV infection
Active CMV infection was defined if one
or more of the following four conditions
were present: 1) two or more positive results
for human CMV DNA by PCR in urine, 2)
CMV antibody seroconversion in a subject
who was seronegative before the transplant,
3) a four-fold or greater increase in IgG
CMV antibodies, and 4) a positive test for
IgM CMV antibodies.
Symptoms consistent with CMV disease
have been previously described (17-21), and
the diagnostic criteria for symptomatic CMV
disease used in our study essentially fol-
lowed the recommendations made by the
Workshop on human CMV disease (19).
Work-up for microorganisms other than
CMV included multiple bacteriological and
fungal cultures of blood, urine and sputum,
as well as serologic tests and multiple chest
X-rays. CMV isolation was not attempted.
Results
Based on the criteria used, 32 (86.4%) of
the 37 subjects had laboratory evidence of
active CMV infection. In six patients, PCR
was the only test, which detected a probable
CMV infection. Using this technique, we
identified viral DNA in 64.9% of the trans-
planted patients. The diagnosis was achieved
earlier by PCR than by serologic tests in
general, and active CMV infection occurred
more frequently in the first four months after
transplantation. A diagnosis of active CMV
infection was obtained for 51.4% of the
patients by ELISA and for 54.1% by IFI
(Table 1).
Thirty-four of the 37 (91.8%) renal re-
cipients were seropositive by ELISA before
transplantation as were 32 of the 35 donors
(91.4%). One hundred percent of the recipi-
ents and their respective donors were found
to be CMV seropositive by IFI before the
transplant.
Only one of 37 patients was seronegative
for CMV (ELISA) and he received a kidney
from a seropositive donor. As a result, he
developed primary CMV infection after the
transplant. Sixteen of the 32 patients (50%)
with an active CMV infection showed clini-
cal manifestations attributable to CMV dis-
ease (Table 2). However, CMV etiology
could only be confirmed in three of these
patients. All of them had pneumonia, with
CMV detected by PCR in bronchoalveolar
lavage in two and by lung histopathology in
one fatal case. Five previously seropositive
patients who did not have an active CMV
infection by the adopted criteria had only
minor clinical complications during follow-
up.
Prolonged unexplained fever occurring
without the discernible involvement of other
organ systems, but usually associated with
malaise, anorexia, fatigue, night sweats,
myalgias and arthralgias, was the most
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Table 1 - Results of serology (ELISA and IFI) and PCR on urine during follow-up of 37 kidney transplant patients
who presented active CMV infection.
D/R = Donor/receptor; + = positive reaction; - = negative reaction; *the numbers after transplantation indicate
the months in which PCR and/or serology were indicative of active CMV infection; SC = seroconversion; Not
detected = no seroconversion and/or increase in IgG antibody levels during follow-up.
Patients Before transplantation After transplantation*
Seroconversion and/or
increase in IgG antibody
levels detected by
IgG ELISA PCR PCR IgM ELISA IgM IFI ELISA IFI
D/R D/R
1 +/+ -/- 7,8 - - Not detected 8
2 +/+ -/- - - - 4 9
3 +/+ -/- 1,2,3,9 - - Not detected Not detected
4 -/- -/+ 1 1 - Not detected Not detected
5 +/+ -/- 2,4,6 - - 2,3,4,6 2,4,6
6 +/+ -/- 1,3,5,6 - - Not detected Not detected
7 +/+ -/- - - - Not detected Not detected
8 +/+ -/- 3,6 1,2,3,4 - 1,2,3,4,6 Not detected
9 +/+ -/- 5,7 - - Not detected 7
10 +/+ -/+ 2 - - Not detected Not detected
11 +/+ -/- 2,3 - - Not detected Not detected
12 +/+ -/+ 3,4,5,7 2,3,4,5,7 - Not detected Not detected
13 +/- -/- 2,3,4,5,6 1,2,3,4,5,6 2,3,4 SC(2) SC(2)
14 +/+ -/- - - 2,4 2,4,10 Not detected
15 +/+ -/- 1,2,3,4 - - Not detected Not detected
16 +/+ -/- 4,6,10 - - 2,4,6,10 2,4,6,10
17 +/+ -/+ 5 - - Not detected 5,9,10,11
18 -/+ -/- - - - Not detected Not detected
19 +/+ -/- - - 3,4 3,4 Not detected
20 +/+ -/- - - - Not detected Not detected
21 +/+ -/- 2,3,6,8 - 8 Not detected Not detected
22 +/+ -/+ 3,4,8 - - 3,4 Not detected
23 +/+ -/+ 1 - 1 3,6,7 Not detected
24 +/+ -/- 3,4 - - Not detected Not detected
25 -/- -/- - - - Not detected Not detected
26 +/+ -/- - - 2,7 Not detected Not detected
27 +/+ -/+ 3 - 7 Not detected Not detected
28 +/+ -/- - 5,9,11 5,9,11 5,9,11 Not detected
29 +/+ -/- 3,5 3,4 - Not detected Not detected
30 +/+ -/- - - - 4 Not detected
31 +/+ -/+ 3,4 4,5 5 5 4,5
32 +/+ -/- - - - 3,5,6 1,2,3
33 +/+ -/- - - 6 Not detected 5,6
34 +/+ -/+ 3,5 - 5 5 Not detected
35 +/+ -/- - - - Not detected Not detected
36 +/+ -/+ 1,6 - - 6 6
37 +/+ -/- 3 - - 3 3
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common symptom observed in patients who
developed CMV infection (11 patients)
(Table 2). All of these patients had fever
³38oC for at least one week without other
detectable infectious causes. All patients with
active CMV infection had at least one of the
following manifestations in addition to fe-
ver: 1) leukopenia (white blood cells <4,000/
mm3); 2) thrombocytopenia (platelets
<100,000/mm3); 3) hepatitis (serum alanine
aminotransferase >40 IU) and 4) atypical
lymphocytosis ³3%).
Discussion
Cytomegalovirus infection remains a
major cause of morbidity and mortality in
the immunocompromised patient, and is the
most serious problem in organ allograft re-
cipients. The possibility of using specific
antiviral therapy to treat CMV infections
makes a timely diagnosis imperative (21-
34). To overcome the time disadvantage of a
cell culture assay, investigators have used
PCR to amplify CMV specific sequences
and have demonstrated its usefulness for
monitoring CMV infection in renal trans-
plant patients (25,26).
To our knowledge, this is the first study
in Brazil to use PCR to detect CMV infection
in renal transplant patients. With this tech-
nique, we identified viral DNA in 64.9% of
the transplanted patients. The findings of
Rowley et al. (25) and Chen et al. (22)
suggest that the PCR assay is only capable of
detecting CMV viral DNA in patients with
an active infection and that it is not positive
in seropositive healthy individuals or in se-
ropositive transplant patients without other
evidence of active CMV infection. Remark-
ably, we did not find positive CMV PCR in
over 200 urine samples from seropositive
healthy adults used as controls (data not
shown). The results of our study are compa-
rable to those of Olive et al. (26) who con-
cluded that PCR was more sensitive than
ELISA and cell culture in detecting CMV in
renal transplant patients.
The predominant clinical feature detected
in patients with evidence of active CMV
infection was fever (70%). Other relevant
clinical manifestations included hepatitis with
negative tests for hepatitis viruses A, B and
C, leukopenia, and interstitial pulmonary in-
Table 2 - Clinical features of patients who developed CMV infection.
(+) Fatal illness.
Patients Clinical findings in probable and confirmed* CMV infection Days after transplantation
6 Fever, myalgias and cough 150
10 Compromised renal function, without cellular rejection 60
12 Unexplained fever 210
13 Fever, leukopenia, splenomegaly 30
14 Generalized lymphadenopathy 13
16 Fever, myalgias and cough 300
17 Compromised renal function, without cellular rejection 150
22 Hepatitis with leukopenia 90
23(+)* Fever, dyspnea and interstitial pulmonary infiltration 30
27 Leukopenia 90
28 Unexplained fever 330
29* Fever and cough 45
31 Fever, myalgia and fatigue 150
32* Fever and interstitial pulmonary infiltration 30
34 Fever, myalgia and fatigue 45
36 Prolonged unexplained fever 30
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filtrates associated with detection of CMV in
bronchoalveolar lavage and in a lung biopsy
by PCR. We also observed compromised
renal function in two cases for which a graft
biopsy did not demonstrate a well-defined
cellular rejection.
In agreement with data in the literature,
the clinical manifestations observed in pa-
tients who were CMV seropositive before
transplantation were not severe and resolved
spontaneously, except for one patient (No.
23) who died.
In a previous study conducted in Brazil
(35), a CMV infection was diagnosed in
5.3% of the patients based exclusively on
serological methods (complement fixation
and IFI). Another study using viral cultures
and serological methods (complement fixa-
tion and IFI) (36) detected CMV infection in
26% of the patients. In these two studies, as
well as in the present one, there was an
absolute predominance of live over dead
donors. The different frequencies of CMV
infection obtained in these studies probably
reflect methodological differences. The first
of them (35) was retrospective and based the
diagnosis of CMV infection on serological
methods that are regarded as somewhat un-
reliable. The frequency of CMV infection in
the present study was greater than in previ-
ous studies (35,36), probably because of the
high sensitivity of PCR in detecting CMV
together with a longer follow-up period.
In the present study, 32 patients showed
evidence of active CMV infection. In 13
(40.6%) of them, renal function was com-
promised one year after the transplant. In
five, the graft was unsuccessful, two died
and three underwent hemodialysis or perito-
neal dialysis. In five of the 37 patients who
showed no evidence of active CMV infec-
tion or any relevant clinical problems, renal
function was maintained one year after the
transplant. In view of the small number of
patients studied, these results do not permit
statistical analysis but show a tendency to-
wards more frequent loss of renal function in
patients with active CMV infection.
The utilization of techniques such as PCR
that permit the rapid diagnosis of CMV in-
fection improves the chances for implemen-
tation of specific antiviral treatment. The
finding that 86.4% of the patients developed
CMV infection underscores the frequency
of this problem in renal transplant patients in
Brazil.
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